Birch bark extract as therapy for chronic hepatitis C – A pilot study

Saint Petersburg State Medical Academy named after I.I. Mechnikov, 47, Piskarevsky pr., 195067 Saint Petersburg, Russia.
Phytomedicine: international journal of phytotherapy and phytopharmacology (Impact Factor: 3.13). 03/2011; 18(10):807-10. DOI: 10.1016/j.phymed.2011.01.021
Source: PubMed


The hepatoprotective effect of birch bark extract (BBE) in patients with chronic hepatitis C (CHC) was studied. Forty-two patients with serologically confirmed chronic hepatitis C were treated for 12 weeks with 160 mg standardized BBE per day. The primary outcome parameter measured was the rate of alanine aminotransferase (ALT) normalization after 12 weeks. Secondary parameters included the course of ALT, aspartate aminotransferase (AST) levels, quantitative HCV RNA levels, subjective symptoms associated with CHC (fatigue, abdominal discomfort, depression, and dyspepsia), safety and compliance. The qualitative-quantitative analysis of BBE was made using high performance liquid chromatography to confirm the presence of 75% betulin and 3.5% betulinic acid. Significant differences in the mean ALT and HCV RNA levels were observed after 12 weeks of treatment. The level of ALT was decreased in 54.0% and normalized (p=0.046). HCV RNA was reduced in 43.2% (p=0.016). After 12 weeks of treatment, reports of fatigue and abdominal discomfort were reduced by 6-fold (p=0.028) and 3-fold (p=0.05), respectively. Dyspepsia was no longer reported (p=0.042) and the effect was significantly different from baseline. Because this study lacks a control group clinical relevance of the data can only be estimated in future by following controlled clinical trials.

Download full-text


Available from: Alexander N Shikov, Oct 16, 2014
53 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In order to evaluate the content of betulin and betulinic acids in Birch barks originating from Western Carpathians, Transylvania (Romania) forests, in relation with the location of birch trees, it was recorded the geographic and vegetation conditions at the specific locations of each type of sample. Two groups of birch tree bark (totally 10 samples) were collected, from two regions, pasture surfaces where birch trees appeared spontaneously (samples 1 to 5) and another group from forests of combined trees, including mainly pine trees (samples 6 to 10). The identification and quantitation of betulin and betulinic acid were made by High Performance Liquid Chromatography with UV detection. In the first region it has been found mean concentrations of 126.85 ± 12.56 mg/g betulin bark while acid betulinic had average values of 12.78 ± 1.26 mg/g bark. In the second region we found mean concentrations of 89.84 ± 8.43 mg/g betulin of bark while acid betulinic had average values of 10.60 ± 0.97 mg/g bark. Statistically, significant differences were noticed between the two regions, the first region being richer in these molecules. Generally, the percentage of betulinic acid was around 11.23% against betulin, higher in the second region, even the absolute concentrations were lower for both molecules. These data are useful indicators of the potential offered by birch bark sources found in Transylvania region, to obtain extracts enriched in betulin and betulinic acid.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the effects of fucoidan, a complex sulfated polysaccharide extract from marine seaweed, on hepatitis C virus (HCV) RNA load both in vitro and in vivo. HCV-1b replicon-expressing cells were cultured in the presence of fucoidan obtained from Cladosiphon okamuranus Tokida cultivated in Okinawa, Japan, and quantified the level of HCV replication. In an open-label uncontrolled study, 15 patients with chronic hepatitis C, and HCV-related cirrhosis and hepatocellular carcinoma were treated with fucoidan (0.83 g/d) for 12 mo. The clinical symptoms, biochemical tests, and HCV RNA levels were assessed before, during, and after treatment. Fucoidan dose-dependently inhibited the expression of HCV replicon. At 8-10 mo of treatment with fucoidan, HCV RNA levels were significantly lower relative to the baseline. The same treatment also tended to lower serum alanine aminotransferase levels, and the latter correlated with HCV RNA levels. However, the improved laboratory tests did not translate into significant clinical improvement. Fucoidan had no serious adverse effects. Our findings suggest that fucoidan is safe and useful in the treatment of patients with HCV-related chronic liver diseases. Further controlled clinical trials are needed to confirm the present findings.
    World Journal of Gastroenterology 05/2012; 18(18):2225-30. DOI:10.3748/wjg.v18.i18.2225 · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Orthorhombic (s.g. P 21 21 2, a = 28.6145 Å, b = 27.4115 Å, c = 6.9536 Å, V = 5454.1 Å3) betulin (C30H50O2) was found in this study to melt at 245 °C with the enthalpy of fusion 40.3 J mol−1. The shape of the peak of melting gives rise to the belief that there are several polymorphs of betulin.
    Journal of Thermal Analysis and Calorimetry 03/2013; 111(3). DOI:10.1007/s10973-012-2235-4 · 2.04 Impact Factor
Show more